pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
lower estim reflect failur epacadostat trial make slight
adjust oper expens decid want double-down effort
order creat life jakafi given patent expiri year want drive toward
profit pare deliv value-multipl build cash posit potenti
meaning biz dev strateg option beyond compani continu sound
approach despit failur epacadostat still need find new flag bearer take
mega-jakafi franchis gener appear inde mani year away also
signific work ahead defin
fda ad baricitinib expect approv high bearish
biotech tape risk-reward event skew neg furthermor convinc
lly/inci gener enough data support approv although highli debat
remain in-lin rate new pt
failur studi epacadostat melanoma hr morn come
lesson view
ido inhibit may dead actual dont think pathway biopsi data
indic highli variabl effect ido inhibit intratumor kyneurin level along
fact ido tdo lead kyneurin product two mani basic biolog
flaw epacadostat stori privat compani kyn actual work
downstream pathway approach still find conceptu quit interest
care drug dont show monotherapi activ great invok term like hot
tumor cold tumor synergist mechan action much dont
know cancer immunotherapi biolog obsess focu lymphocyt miss
fact innat immun system even import evok immun
meticul oncolog cross trial comparison especi ad inhibit
consider variabl respons antibodi depend tumor size stage
mutat burden express compar dataset even data subset fraught
peril therapi limit monotherapi activ care come
life combo trial data seem differenti antibodi alon
might accomplish
call manag note epacadostat phase studi underway
tumor type continu earli enough allow modif statist analys
etc discuss partner analysi studi given
view biolog see limit probabl success
model revis lower revenu estim reflect epacadostat failur also lower
termin growth reflect compani approach major patent cliff end model
without obviou new driver perform lower oper expens slightli off-set
valuat basi pt base dcf use discount rate appli
commerci stage biotech compani termin growth rate equat termin multipl jakafi
generic like toward latter half next decad believ reason termin growth assumpt
includ contribut jakafi et gvhd well eventu launch olumi model
contribut epacadostat howev includ meaning gener catch-al line item
captur program fgfr inhibitor inhibitor
risk upsid risk in-lin rate includ better-than-expect perform jakafi includ success et
gvhd believ drive share around quarterli earn pipelin program success epacadostat
compound rapid margin expans optim cash flow jakafi abil find near-term path forward
olumi downsid risk in-lin rate includ failur epacadostat pipelin program increas competit
threat and/or delay olumi continu aggress develop spend jakafi patent expiri draw near caus
investor concern regard valuat
articl articl
time dissemin april et
analyst josh schimmer steven breazzano maneka mirchandaney ami liu primarili respons prepar
research report attest follow view opinion render research report reflect person view
subject compani issuer part research analyst compens directli relat specif
recommend view research report
